In honor of National Stroke Awareness Month (May), Team AFib invites you to our inaugural webinar “AFib: When Stroke Strikes”, hosted by the National Stroke Association. A live expert panel will help you learn to recognize and respond quickly to afib stroke signs and symptoms. StopAfib.org is a member of Team AFib. To learn more …
Read More
A study presented at the recent American College of Cardiology Scientific Sessions by Dr. Matthew Reynolds of the Harvard Clinical Research Institute showed that having a radiofrequency (RF) catheter ablation for atrial fibrillation could reduce the risk of stroke by 40% compared to those who did not have an ablation. To learn more, see: Radiofrequency …
Read More
Dr. John Mandrola shares a great update on the latest info regarding dabigatran (Pradaxa, Pradax). Dr. Mandrola not only treats atrial fibrillation patients, but he has also experienced afib himself. I have become an AF-doctor. That means my most exciting aspect of medicine is terminating AF with watts delivered through a catheter. “Got it.” In …
Read More
Mellanie True Hills, founder of StopAfib.org, recently spoke at the Fourth Annual Western Atrial Fibrillation Symposium. Many of her remarks to this medical conference are summarized in an article just published in EP Lab Digest. You may wish to share it with family and friends who need to understand what it's like to live with …
Read More
In this video, Dr. Matthew Reynolds, of the Harvard Clinical Research Institute, discussed his quality of life findings from use of catheter ablation and antiarrhythmic drugs for treatment of atrial fibrillation. He analyzed quality of life data that was collected as part of the THERMOCOOL catheter trial in which catheter ablation was found to be …
Read More
You're invited to join us for the launch of The Silver Book®: Thrombosis on March 23, 2011, at the Rayburn House Office Building on Capitol Hill in Washington, DC. If you can't make it, see how you can order a copy of the book, which features statistics on atrial fibrillation and strokes. See: Atrial Fibrillation …
Read More
Note: In meetings with the FDA last week, representatives from WomenHeart and StopAfib.org became aware of the risk that potential funding cuts may significantly delay the FDA's work in reviewing and approving afib drugs and devices. Because of the potential impact on the afib community, we are publishing comments from WomenHeart as to what those …
Read More
Researchers at the Comprehensive Arrhythmia Research and Management Center (CARMA) in Utah have been studying the relationship between atrial fibrillation, atrial fibrosis, and catheter ablation outcomes for many years. Now, they’ve applied their knowledge of quantifying atrial fibrosis to stroke risk assessment and found that the amount of atrial fibrosis, not type of afib, is …
Read More
New research from Denmark shows that CHADS2 underestimates stroke risk. In the study, atrial fibrillation patients who were at intermediate risk with the CHADS2 scoring system had more than twice the stroke rate of those defined by the enhanced CHA2DS2-VASc tool as being at intermediate risk. While CHADS2 deemed 32.3% of patients to have intermediate …
Read More
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
Read More